Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France.
Antiviral Res. 2023 Aug;216:105672. doi: 10.1016/j.antiviral.2023.105672. Epub 2023 Jul 14.
Data on herpes simplex virus (HSV) polymorphism as well as acyclovir (ACV) and foscarnet (FOS) resistance mutations are not exhaustive and may hinder accurate diagnosis by next-generation sequencing (NGS). Here, we report novel UL23 and UL30 substitutions for HSV1 and HSV2 identified in immunocompromised patients treated for hematological malignancies during the last 6 years of HSV resistance surveillance at the University Hospital of Lyon. For HSV1, 35 novel UL23 substitutions and 52 novel UL30 substitutions were identified. For HSV2, 2 novel UL23 substitutions and 12 novel UL30 substitutions were identified. These results allow to complete the database of HSV1 and HSV2 substitutions, related either to polymorphism or to ACV and FOS resistance.
有关单纯疱疹病毒 (HSV) 多态性以及阿昔洛韦 (ACV) 和膦甲酸 (FOS) 耐药突变的数据并不详尽，可能会阻碍下一代测序 (NGS) 的准确诊断。在这里，我们报告了在里昂大学医院进行 HSV 耐药监测的最后 6 年中，针对血液恶性肿瘤患者进行治疗时发现的免疫功能低下患者的 HSV1 和 HSV2 的新型 UL23 和 UL30 取代物。对于 HSV1，鉴定出 35 种新型 UL23 取代物和 52 种新型 UL30 取代物。对于 HSV2，鉴定出 2 种新型 UL23 取代物和 12 种新型 UL30 取代物。这些结果使 HSV1 和 HSV2 取代物的数据库得以完善，这些取代物与多态性或 ACV 和 FOS 耐药性有关。
